Enzalutamide
Information
- Drug Name
- Enzalutamide
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| prostate cancer | PTEN MUTATION PTEN MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25544636 | Detail |
| prostate cancer |
AR p.Phe877Leu (p.F877L) ( ENST00000374690.9, ENST00000396044.8 ) AR p.Phe877Leu (p.F877L) ( ENST00000374690.9, ENST00000396044.8 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 23779130 | Detail |
| prostate cancer | AR SPLICE VARIANT 7 AR SPLICE VARIANT 7 | B |
Predictive
|
Supports
|
Resistance |
N/A
|
3 | 25184630 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Castrated mice bearing androgen-sensitive human pr... | PTEN | PTEN MUTATION PTEN MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Mutations F876L in the ligand binding domain of th... | AR |
AR p.Phe877Leu (p.F877L) ( ENST00000374690.9, ENST00000396044.8 ) AR p.Phe877Leu (p.F877L) ( ENST00000374690.9, ENST00000396044.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Detection of AR-V7 in circulating tumor cells of 6... | AR | AR SPLICE VARIANT 7 AR SPLICE VARIANT 7 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06013475 | Active, not recruiting | An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings | August 31, 2023 | August 31, 2024 | |
| NCT04419402 | Active, not recruiting | Phase 2 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer | August 17, 2020 | January 1, 2025 |
| NCT02677896 | Active, not recruiting | Phase 3 | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | March 9, 2016 | July 31, 2024 |
| NCT02007512 | Active, not recruiting | Phase 2 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | December 13, 2013 | June 28, 2024 |
| NCT04381832 | Active, not recruiting | Phase 1/Phase 2 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | July 7, 2020 | August 2024 |
| NCT04332744 | Active, not recruiting | Phase 2 | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | September 2, 2020 | July 31, 2025 |
| NCT01885949 | Active, not recruiting | Phase 2 | Tivozanib + Enzalutamide in Adv Prostate Cancer | September 3, 2013 | June 2026 |
| NCT02023463 | Active, not recruiting | Phase 1 | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | April 2, 2014 | January 1, 2040 |
| NCT02430480 | Active, not recruiting | Phase 2 | Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | June 3, 2015 | June 1, 2025 |
| NCT05968599 | Active, not recruiting | A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer | July 24, 2023 | December 31, 2024 | |
| NCT02750358 | Active, not recruiting | Phase 2 | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | May 19, 2016 | May 2024 |
| NCT04262154 | Active, not recruiting | Phase 2 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | March 3, 2020 | September 2026 |
| NCT02099864 | Active, not recruiting | Phase 2 | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | February 5, 2014 | June 1, 2024 |
| NCT02446405 | Active, not recruiting | Phase 3 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | March 2014 | December 2024 |
| NCT02446444 | Active, not recruiting | Phase 3 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | March 2014 | December 2025 |
| NCT02452008 | Active, not recruiting | Phase 2 | Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | May 3, 2016 | December 2025 |
| NCT04207255 | Active, not recruiting | Phase 2 | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | March 27, 2020 | May 31, 2024 |
| NCT02278185 | Active, not recruiting | Phase 2 | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | November 11, 2015 | April 10, 2025 |
| NCT02194842 | Active, not recruiting | Phase 3 | Phase III Radium 223 mCRPC-PEACE III | October 2015 | December 2028 |
| NCT04191096 | Active, not recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | February 12, 2020 | June 15, 2026 |
| NCT04179864 | Active, not recruiting | Phase 1/Phase 2 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer | November 18, 2019 | June 28, 2024 |
| NCT02955394 | Active, not recruiting | Phase 2 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | September 21, 2017 | February 2027 |
| NCT01949337 | Active, not recruiting | Phase 3 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | January 22, 2014 | August 31, 2024 |
| NCT05457257 | Active, not recruiting | Phase 4 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | July 29, 2022 | September 30, 2025 |
| NCT05404139 | Active, not recruiting | Phase 2 | Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | May 24, 2023 | March 2026 |
| NCT03809000 | Active, not recruiting | Phase 2 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery | April 15, 2019 | September 15, 2029 |
| NCT02203695 | Active, not recruiting | Phase 2 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | March 28, 2015 | December 2024 |
| NCT02294461 | Active, not recruiting | Phase 3 | An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | April 23, 2014 | June 30, 2024 |
| NCT01990196 | Active, not recruiting | Phase 2 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | September 23, 2014 | September 30, 2025 |
| NCT04076059 | Active, not recruiting | Phase 3 | An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | September 11, 2019 | December 31, 2028 |
| NCT05202301 | Active, not recruiting | A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | January 15, 2022 | June 30, 2024 | |
| NCT02522715 | Active, not recruiting | Phase 1/Phase 2 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | October 13, 2015 | July 1, 2024 |
| NCT04934722 | Active, not recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | May 25, 2021 | June 15, 2026 |
| NCT04034095 | Active, not recruiting | A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan | July 8, 2019 | October 8, 2025 | |
| NCT02312557 | Active, not recruiting | Phase 2 | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | November 18, 2014 | June 30, 2024 |
| NCT03314324 | Active, not recruiting | Phase 2 | A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer | November 29, 2017 | October 2024 |
| NCT02319837 | Active, not recruiting | Phase 3 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | December 17, 2014 | September 19, 2026 |
| NCT03939689 | Active, not recruiting | Phase 2 | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone | May 30, 2019 | September 24, 2024 |
| NCT03338790 | Active, not recruiting | Phase 2 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | December 19, 2017 | September 15, 2024 |
| NCT03344211 | Active, not recruiting | Phase 2 | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | November 21, 2018 | November 21, 2025 |
| NCT02339168 | Active, not recruiting | Phase 1 | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | June 22, 2016 | December 2025 |
| NCT00268476 | Active, not recruiting | Phase 2/Phase 3 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | July 8, 2005 | December 2030 |
| NCT02003924 | Active, not recruiting | Phase 3 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer | October 31, 2013 | October 31, 2024 |
| NCT03860987 | Active, not recruiting | Phase 2 | Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | April 30, 2019 | August 1, 2028 |
| NCT04647526 | Active, not recruiting | Phase 3 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | February 25, 2021 | March 2028 |
| NCT03850795 | Active, not recruiting | Phase 3 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | March 15, 2021 | December 31, 2024 |
| NCT04455750 | Active, not recruiting | Phase 3 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy | February 19, 2021 | September 2026 |
| NCT03700099 | Active, not recruiting | Phase 2 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | September 3, 2019 | April 1, 2025 |
| NCT04446117 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | June 30, 2020 | August 31, 2024 |
| NCT03834493 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | July 28, 2019 | May 31, 2024 |
| NCT02366494 | Active, not recruiting | Micro RNAs to Predict Response to Androgen Deprivation Therapy | April 29, 2015 | June 2025 | |
| NCT02384382 | Completed | Phase 2 | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | November 30, 2015 | May 3, 2019 |
| NCT02407054 | Completed | Phase 2 | A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | April 29, 2015 | April 16, 2020 |
| NCT02429193 | Completed | Phase 2 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA | March 2016 | September 1, 2019 |
| NCT05701007 | Completed | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | February 13, 2023 | April 10, 2024 | |
| NCT02453009 | Completed | Phase 2 | Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer | October 2014 | April 2019 |
| NCT05520138 | Completed | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | August 29, 2022 | June 30, 2023 | |
| NCT02485691 | Completed | Phase 4 | Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | November 9, 2015 | March 15, 2021 |
| NCT02495974 | Completed | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | September 8, 2015 | February 8, 2019 | |
| NCT05362149 | Completed | An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings | April 4, 2022 | June 30, 2023 | |
| NCT02507570 | Completed | Phase 2 | Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis | September 23, 2015 | January 18, 2019 |
| NCT02528643 | Completed | Phase 2 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | November 9, 2015 | February 9, 2021 |
| NCT02532114 | Completed | Phase 1 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | December 31, 2015 | November 30, 2017 |
| NCT02555189 | Completed | Phase 1/Phase 2 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | December 1, 2015 | September 1, 2023 |
| NCT02588001 | Completed | N/A | Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide | October 1, 2015 | March 31, 2021 |
| NCT03778047 | Completed | Phase 1 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | February 7, 2018 | August 28, 2019 |
| NCT02642913 | Completed | Phase 1 | Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | December 2015 | March 1, 2021 |
| NCT02669771 | Completed | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | November 30, 2014 | November 30, 2018 | |
| NCT02684227 | Completed | Phase 2 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | August 24, 2016 | September 27, 2023 |
| NCT02689427 | Completed | Phase 2 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | September 22, 2016 | November 15, 2023 |
| NCT02711956 | Completed | Phase 1/Phase 2 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | December 2016 | November 2019 |
| NCT02740985 | Completed | Phase 1 | A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | June 17, 2016 | March 31, 2023 |
| NCT04290611 | Completed | a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY | January 1, 2019 | April 8, 2023 | |
| NCT02799745 | Completed | Phase 2 | A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance | June 9, 2016 | August 28, 2020 |
| NCT02814968 | Completed | Phase 2 | PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide | February 2015 | December 2020 |
| NCT02815033 | Completed | Phase 2 | Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide | July 2015 | December 2020 |
| NCT02833883 | Completed | Phase 1 | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | July 2016 | January 13, 2023 |
| NCT02903160 | Completed | Phase 2 | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | January 13, 2017 | November 15, 2021 |
| NCT02918968 | Completed | Phase 4 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | November 2, 2016 | March 27, 2020 |
| NCT04179396 | Completed | Phase 1 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | December 5, 2019 | January 18, 2023 |
| NCT02987543 | Completed | Phase 3 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | February 6, 2017 | February 15, 2023 |
| NCT03016312 | Completed | Phase 3 | A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen | January 10, 2017 | December 20, 2022 |
| NCT03123978 | Completed | Phase 1 | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | January 9, 2017 | April 19, 2022 |
| NCT04094519 | Completed | Phase 1 | A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | January 27, 2020 | December 27, 2020 |
| NCT04087174 | Completed | Phase 1 | A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | August 5, 2019 | June 22, 2021 |
| NCT03207529 | Completed | Phase 1 | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer | June 7, 2019 | December 31, 2023 |
| NCT03295565 | Completed | Phase 2/Phase 3 | Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | May 7, 2017 | March 2, 2022 |
| NCT03297385 | Completed | Phase 2 | Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation | August 28, 2014 | April 1, 2017 |
| NCT03310541 | Completed | Phase 1 | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | October 11, 2017 | May 3, 2023 |
| NCT03328364 | Completed | A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | December 1, 2017 | December 24, 2017 | |
| NCT03418324 | Completed | Phase 2 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | March 5, 2018 | November 6, 2019 |
| NCT03927391 | Completed | Phase 4 | Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects | May 30, 2019 | January 8, 2024 |
| NCT03896984 | Completed | Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). | March 18, 2019 | December 14, 2020 | |
| NCT03641560 | Completed | Phase 4 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | September 19, 2018 | February 20, 2024 |
| NCT03834519 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | May 2, 2019 | January 27, 2024 |
| NCT03704519 | Completed | Phase 1 | Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers. | October 23, 2018 | November 5, 2019 |
| NCT03751436 | Completed | Phase 1 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | August 2, 2019 | August 11, 2023 |
| NCT02601014 | Completed | Phase 2 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | March 15, 2016 | October 6, 2021 |
| NCT00974311 | Completed | Phase 3 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy | September 30, 2009 | November 2, 2017 |
| NCT01091103 | Completed | Phase 2 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | February 18, 2010 | August 31, 2013 |
| NCT01212991 | Completed | Phase 3 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer | September 16, 2010 | February 14, 2019 |
| NCT01288911 | Completed | Phase 2 | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | March 22, 2011 | November 8, 2017 |
| NCT01302041 | Completed | Phase 2 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | May 6, 2011 | April 27, 2017 |
| NCT01362374 | Completed | Phase 1 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | July 11, 2011 | October 16, 2020 |
| NCT01534052 | Completed | Phase 2 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | October 21, 2011 | April 18, 2017 |
| NCT01547299 | Completed | Phase 2 | Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | March 31, 2012 | November 30, 2013 |
| NCT01597193 | Completed | Phase 1 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | April 30, 2012 | January 22, 2018 |
| NCT01650194 | Completed | Phase 2 | A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | July 9, 2012 | January 4, 2018 |
| NCT01664923 | Completed | Phase 2 | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer | August 2012 | January 2018 |
| NCT01867333 | Completed | Phase 2 | Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | August 12, 2013 | October 26, 2022 |
| NCT01889238 | Completed | Phase 2 | Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | June 12, 2013 | January 10, 2024 |
| NCT01927627 | Completed | Phase 2 | Enzalutamide in Patients With High-risk Prostate Cancer | November 11, 2013 | April 26, 2017 |
| NCT01942837 | Completed | Phase 2 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | September 13, 2013 | September 30, 2022 |
| NCT01946165 | Completed | Phase 2 | Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | October 31, 2013 | July 28, 2017 |
| NCT01974765 | Completed | Phase 2 | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | November 5, 2013 | February 28, 2022 |
| NCT01977651 | Completed | Phase 4 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide | September 25, 2013 | January 11, 2019 |
| NCT01981122 | Completed | Phase 2 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | September 2013 | June 30, 2017 |
| NCT01995513 | Completed | Phase 4 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | October 22, 2013 | August 31, 2022 |
| NCT02012296 | Completed | Phase 1/Phase 2 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | December 13, 2013 | August 1, 2020 |
| NCT02028988 | Completed | Phase 2 | Enzalutamide + External Beam Rt For Prostate | February 2014 | January 2018 |
| NCT02034552 | Completed | Phase 2 | A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | March 7, 2014 | June 26, 2018 |
| NCT02057939 | Completed | Phase 2 | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | April 2014 | June 5, 2019 |
| NCT02058706 | Completed | Phase 2 | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | May 2014 | March 1, 2021 |
| NCT02064582 | Completed | Phase 2 | Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | May 2014 | June 9, 2018 |
| NCT02090114 | Completed | Phase 2 | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | August 25, 2014 | November 11, 2021 |
| NCT02091960 | Completed | Phase 2 | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | September 5, 2014 | January 30, 2024 |
| NCT02116582 | Completed | Phase 4 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | May 23, 2014 | September 29, 2017 |
| NCT02124668 | Completed | Phase 2 | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | September 23, 2014 | May 25, 2017 |
| NCT02125084 | Completed | Phase 1 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | October 2014 | May 3, 2021 |
| NCT02125357 | Completed | Phase 2 | Sequencing Abiraterone and Enzalutamide in mCRPC | September 2014 | February 4, 2020 |
| NCT02138162 | Completed | Phase 1 | A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men | August 2013 | March 2014 |
| NCT02138383 | Completed | Phase 1 | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | May 22, 2014 | October 7, 2019 |
| NCT02138799 | Completed | Phase 1 | A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men | July 2013 | September 2013 |
| NCT06204302 | Completed | An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States | January 5, 2024 | April 4, 2024 | |
| NCT02199197 | Completed | Phase 2 | Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | June 25, 2014 | October 3, 2019 |
| NCT02204072 | Completed | Phase 1 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | November 11, 2014 | June 1, 2023 |
| NCT02207504 | Completed | Phase 1 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | August 2014 | January 3, 2022 |
| NCT02215096 | Completed | Phase 1 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer | November 13, 2014 | October 3, 2019 |
| NCT02225093 | Completed | Phase 1 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | October 2, 2013 | February 3, 2014 |
| NCT02228265 | Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | March 12, 2013 | February 27, 2020 | |
| NCT02256111 | Completed | Phase 2 | EXTEND Exercise Trial | May 13, 2015 | July 17, 2018 |
| NCT02268175 | Completed | Phase 2 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | October 2014 | December 2021 |
| NCT02286921 | Completed | Phase 2 | Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance | January 2015 | February 21, 2020 |
| NCT02288247 | Completed | Phase 3 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone | December 1, 2014 | March 13, 2024 |
| NCT02288936 | Completed | Phase 2 | Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer | February 5, 2015 | July 22, 2019 |
| NCT02300610 | Completed | Phase 1 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | February 11, 2015 | April 19, 2019 |
| NCT02346578 | Completed | Phase 2 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | December 2014 | January 22, 2019 |
| NCT02353715 | Completed | Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing | July 7, 2015 | November 14, 2018 | |
| NCT04145375 | Enrolling by invitation | Phase 1/Phase 2 | Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol | November 12, 2019 | December 31, 2024 |
| NCT06430411 | Not yet recruiting | Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | May 31, 2024 | December 31, 2031 | |
| NCT05422911 | Not yet recruiting | Phase 2 | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | June 30, 2022 | June 30, 2026 |
| NCT05873192 | Not yet recruiting | Phase 2 | Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | September 30, 2024 | December 31, 2028 |
| NCT06015321 | Not yet recruiting | Phase 2 | An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma | October 1, 2023 | April 30, 2026 |
| NCT06236139 | Not yet recruiting | Phase 1/Phase 2 | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | September 1, 2024 | March 30, 2027 |
| NCT06257693 | Not yet recruiting | Phase 1 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | February 2024 | August 2025 |
| NCT06312670 | Not yet recruiting | Phase 2 | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | August 1, 2024 | March 1, 2026 |
| NCT06332170 | Not yet recruiting | Phase 1 | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | May 30, 2024 | May 30, 2028 |
| NCT03568656 | Recruiting | Phase 1/Phase 2 | Study to Evaluate CCS1477 in Advanced Tumours | July 23, 2018 | March 2024 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT04015622 | Recruiting | Phase 2 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | October 7, 2020 | December 1, 2025 |
| NCT02960022 | Recruiting | Phase 2 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | December 22, 2016 | July 31, 2026 |
| NCT02935205 | Recruiting | Phase 1/Phase 2 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | January 17, 2017 | December 2024 |
| NCT04221542 | Recruiting | Phase 1 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | March 4, 2020 | July 30, 2028 |
| NCT02685397 | Recruiting | Phase 2/Phase 3 | Management of Castration-Resistant Prostate Cancer With Oligometastases | October 2016 | August 2041 |
| NCT04335682 | Recruiting | Phase 2 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | August 17, 2021 | August 2024 |
| NCT04363164 | Recruiting | Phase 2 | Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | August 19, 2020 | July 2026 |
| NCT04471974 | Recruiting | Phase 2 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | January 26, 2021 | April 30, 2027 |
| NCT04557449 | Recruiting | Phase 1/Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | September 23, 2020 | May 4, 2028 |
| NCT04986423 | Recruiting | Phase 2 | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | September 8, 2021 | June 2025 |
| NCT05011188 | Recruiting | Phase 1/Phase 2 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | January 19, 2022 | March 31, 2027 |
| NCT05037500 | Recruiting | Phase 1 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | January 26, 2022 | January 30, 2025 |
| NCT05075577 | Recruiting | Phase 1/Phase 2 | EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC | December 21, 2021 | January 2026 |
| NCT05081193 | Recruiting | Phase 2 | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | March 7, 2022 | December 30, 2027 |
| NCT05112965 | Recruiting | Phase 3 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | December 1, 2021 | December 31, 2025 |
| NCT05212857 | Recruiting | Phase 2 | Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | April 2022 | September 2024 |
| NCT05252390 | Recruiting | Phase 1/Phase 2 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | March 29, 2022 | November 2026 |
| NCT05367440 | Recruiting | Phase 1/Phase 2 | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | June 2, 2022 | August 15, 2030 |
| NCT05393791 | Recruiting | Phase 2 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC | November 10, 2022 | November 10, 2027 |
| NCT05406999 | Recruiting | Phase 2 | Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | February 1, 2020 | June 30, 2030 |
| NCT06228053 | Recruiting | Phase 2 | Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer | June 5, 2024 | June 30, 2028 |
| NCT05526248 | Recruiting | Phase 2 | A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide | December 19, 2022 | May 28, 2026 |
| NCT05726292 | Recruiting | Phase 2 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | October 9, 2023 | April 1, 2029 |
| NCT05730712 | Recruiting | Phase 2 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | March 8, 2024 | October 2025 |
| NCT05733351 | Recruiting | Phase 1 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | August 3, 2023 | December 16, 2027 |
| NCT05743621 | Recruiting | Phase 1 | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | November 20, 2023 | November 2027 |
| NCT05751941 | Recruiting | Phase 2 | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | February 14, 2023 | October 2025 |
| NCT05818683 | Recruiting | Phase 1 | A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | April 26, 2023 | September 1, 2027 |
| NCT06378866 | Recruiting | Phase 2 | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | June 3, 2024 | May 31, 2029 |
| NCT05901649 | Recruiting | A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | July 5, 2023 | September 5, 2025 | |
| NCT06059118 | Recruiting | Phase 2 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | October 4, 2023 | November 30, 2029 |
| NCT06096870 | Recruiting | Phase 2 | Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | April 22, 2024 | December 31, 2029 |
| NCT06099769 | Recruiting | Phase 2 | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | October 18, 2023 | October 2027 |
| NCT06120491 | Recruiting | Phase 3 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | November 21, 2023 | April 30, 2031 |
| NCT06136624 | Recruiting | Phase 3 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | December 31, 2023 | August 2, 2028 |
| NCT06136650 | Recruiting | Phase 3 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | December 18, 2023 | December 2, 2030 |
| NCT03768063 | Recruiting | Phase 3 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | February 28, 2019 | July 5, 2028 |
| NCT03674814 | Recruiting | Phase 1 | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | October 23, 2018 | March 10, 2026 |
| NCT02438007 | Terminated | Phase 3 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC | June 2015 | November 2016 |
| NCT02885649 | Terminated | Early Phase 1 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | December 5, 2017 | March 2, 2020 |
| NCT02500901 | Terminated | Phase 1 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | March 2016 | May 10, 2016 |
| NCT02758132 | Terminated | Phase 2 | Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | March 1, 2016 | September 6, 2016 |
| NCT03829930 | Terminated | Phase 1 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | May 1, 2019 | September 1, 2020 |
| NCT02491411 | Terminated | N/A | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | September 2015 | March 2018 |
| NCT02685267 | Terminated | Phase 2 | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | February 2016 | August 2017 |
| NCT04409288 | Terminated | Phase 3 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | July 20, 2020 | October 16, 2023 |
| NCT02640534 | Terminated | Phase 2 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | June 10, 2016 | March 16, 2023 |
| NCT02607228 | Terminated | Phase 1/Phase 2 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer | December 8, 2015 | September 3, 2019 |
| NCT04456049 | Terminated | Phase 2 | Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1 | August 24, 2020 | June 9, 2021 |
| NCT03685591 | Terminated | Phase 1 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | October 4, 2018 | March 30, 2022 |
| NCT04631601 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | January 15, 2021 | October 23, 2023 |
| NCT02605863 | Terminated | Phase 2 | Enzalutamide for Bladder Cancer Chemoprevention | January 2016 | February 2018 |
| NCT02489123 | Terminated | Phase 2 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | August 11, 2015 | June 16, 2020 |
| NCT02457910 | Terminated | Phase 1/Phase 2 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | June 2015 | August 8, 2022 |
| NCT02441517 | Terminated | Phase 4 | A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment | October 28, 2015 | March 15, 2017 |
| NCT03531827 | Terminated | Phase 2 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | March 26, 2019 | June 1, 2021 |
| NCT03999515 | Terminated | Phase 2 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | April 27, 2020 | June 6, 2021 |
| NCT02508636 | Terminated | Phase 2 | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer | December 22, 2015 | August 31, 2020 |
| NCT03300505 | Terminated | Phase 1 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | May 31, 2019 | January 24, 2023 |
| NCT04052204 | Terminated | Phase 1/Phase 2 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | December 30, 2019 | September 29, 2020 |
| NCT03150056 | Terminated | Phase 1 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | July 18, 2017 | June 22, 2021 |
| NCT04142060 | Terminated | Phase 2 | Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC | June 1, 2020 | October 10, 2022 |
| NCT04157088 | Terminated | Phase 2 | Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) | December 17, 2019 | July 8, 2022 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT03196388 | Unknown status | Phase 2 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer | December 27, 2017 | December 2018 |
| NCT02676986 | Unknown status | Phase 2 | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer | August 2015 | March 2020 |
| NCT03124615 | Unknown status | Phase 2 | Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer | May 2017 | June 2021 |
| NCT04116775 | Unknown status | Phase 2 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | October 30, 2019 | October 2023 |
| NCT02525068 | Unknown status | Phase 2 | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC | December 2014 | March 2020 |
| NCT03016741 | Unknown status | Phase 4 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | March 31, 2017 | August 2023 |
| NCT02749903 | Unknown status | Phase 2 | Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | June 2016 | July 5, 2022 |
| NCT03753243 | Unknown status | Phase 2 | Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer | December 3, 2018 | April 30, 2023 |
| NCT03480646 | Unknown status | Phase 1/Phase 2 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | November 15, 2017 | December 2021 |
| NCT03336983 | Unknown status | Phase 2 | Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | December 1, 2017 | December 1, 2023 |
| NCT02929576 | Withdrawn | Phase 3 | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer | September 2016 | |
| NCT01663415 | Withdrawn | Phase 2 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | August 2012 | October 2014 |
| NCT05191017 | Withdrawn | Phase 1/Phase 2 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | September 2022 | July 2026 |
| NCT02159690 | Withdrawn | Phase 2 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | September 2014 | January 2015 |
| NCT02380313 | Withdrawn | Phase 1 | Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone | October 2015 | May 2017 |
| NCT03709550 | Withdrawn | Phase 1/Phase 2 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | April 15, 2021 | April 15, 2024 |